Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$316.22 USD

316.22
184,445

-1.80 (-0.57%)

Updated Jul 23, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Surging Earnings Estimates Signal Good News for West Pharmaceutical (WST)

West Pharmaceutical (WST) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up

CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates

Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall

Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip

Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1

STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.

The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services

The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services

LabCorp (LH) Banks on Covance Amid Testing Volume Pressure

LabCorp's (LH) COVID-19 related research too has been progressing well.

Bet on These 5 Low Leverage Stocks This Earnings Season

Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently

McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates

McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.

Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand

Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.

Nalak Das headshot

Wall Street is Northbound Defying All Concerns: 5 Top Picks

A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.

IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise

IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.

Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract

Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.

Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.

Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises

Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.

Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y

Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

Stryker's (SYK) second-quarter earnings reflect weak segmental performance.

OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates

OPKO Health's (OPK) second-quarter results benefit from increase in RAYALDEE prescriptions.